A carregar...
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
BACKGROUND: Bone mineral density (BMD) declines when zoledronic acid (ZA) is administered. This case series describes the patterns of change in BMD when 1 or 2 doses of ZA are administered after denosumab. METHODS: Twelve patients who received at least 2 doses of denosumab followed by at least 1 dos...
Na minha lista:
| Publicado no: | J Bone Metab |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Korean Society for Bone and Mineral Research
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7973401/ https://ncbi.nlm.nih.gov/pubmed/33730783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.11005/jbm.2021.28.1.51 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|